Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival

Molecular Endocrinology

Volumn 26, Issue 12, 2012, Pages 1967-1979

  Peacock, Stephanie O ^a   Fahrenholtz, Cale D ^a   Burnstein, Kerry L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; PLECKSTRIN; PROTEIN VAV3; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION; UPREGULATION;

CASTRATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; MALE; NEOPLASM TRANSPLANTATION; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-VAV; RECEPTORS, ANDROGEN; RNA SPLICING; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS; UP-REGULATION;

EID: 84870352810     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2012-1165     Document Type: Article

References (45)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D 2011 Global cancer statistics. CA Cancer J Clin 61:69-90
2. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ 2003 Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21:1232-1237
3. Dehm SM, Tindall DJ 2006 Molecular regulation of androgen action in prostate cancer. J Cell Biochem 99:333-344
4. Agoulnik IU, Weigel NL 2006 Androgen receptor action in hormonedependent and recurrent prostate cancer. J Cell Biochem 99:362-372
5. Hååg P, Bektic J, Bartsch G, Klocker H, Eder IE 2005 Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 96: 251-258
6. Knudsen KE, Penning TM 2010 Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab 21:315-324
7. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ 2002 Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62:1008-1013
8. Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS 2006 Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res 66:10613-10620
9. Taplin ME, Balk SP 2004 Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 91:483-490
10. Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, Wong EC, Fazli L, Nelson CC, Gleave ME, Rennie PS 2009 In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res 15:39-47
11. Debes JD, Tindall DJ 2004 Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351:1488-1490
12. Dehm SM, Tindall DJ 2011 Alternatively spliced androgen receptor variants. Endocr Relat Cancer 18:R183-R196
13. Guo Z, Qiu Y 2011 A new trick of an old molecule: androgen receptor splice variants taking the stage?! Int J Biol Sci 7:815-822
14. Feldman BJ, Feldman D 2001 The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45
15. Jänne OA, Palvimo JJ, Kallio P, MehtoM1993 Androgen receptor and mechanism of androgen action. Ann Med 25:83-89
16. Gelmann EP 2002 Molecular biology of the androgen receptor. J Clin Oncol 20:3001-3015
17. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG, Kung HJ 2002 Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 62:6606-6614
18. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ 2008 Splicing of a novel androgen receptor exon generates a constitu-tively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68:5469-5477
19. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J 2009 Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69:16-22
20. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y 2009 A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69:2305-2313
21. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL 2010 Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 107: 16759-16765
22. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR 2010 Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120:2715-2730
23. Hörnberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, Bergh A, Wikström P 2011 Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 6:e19059
24. Lyons LS, Burnstein KL 2006 Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity. Mol Endocrinol 20: 1061-1072
25. Lyons LS, Rao S, Balkan W, Faysal J, Maiorino CA, Burnstein KL 2008 Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer. Mol Endocrinol 22:597-608
26. Rao S, Lyons LS, Fahrenholtz CD, Wu F, Farooq A, Balkan W, Burnstein KL 2012 A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer. Oncogene 31:716-727
27. Banach-Petrosky W, Jessen WJ, Ouyang X, Gao H, Rao J, Quinn J, Aronow BJ, Abate-Shen C 2007 Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice. Cancer Res 67:9089-9096
28. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL 2004 Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164:217-227
29. Dong Z, Liu Y, Lu S, Wang A, Lee K, Wang LH, Revelo M, Lu S 2006 Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. Mol Endocrinol 20:2315-2325
30. Lin KT, Gong J, Li CF, Jang TH, Chen WL, Chen HJ, Wang LH 2012 Vav3-rac1 signaling regulates prostate cancer metastasis with elevated vav3 expression correlating with prostate cancer progression and posttreatment recurrence. Cancer Res 72:3000-3009
31. Liu Y, Mo JQ, Hu Q, Boivin G, Levin L, Lu S, Yang D, Dong Z, Lu S 2008 Targeted overexpression of vav3 oncogene in prostatic epithelium induces nonbacterial prostatitis and prostate cancer. Cancer Res 68:6396-6406
32. Abramoff MD, Magalhaes PJ, Ram SJ 2004 Image processing with ImageJ. Biophoton Int 11:36-42
33. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Jänne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, et al. 2009 Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138:245-256
34. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG 1993 Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 53:3976-3985
35. Lamont KR, Tindall DJ 2011 Alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol 25:897-907
36. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs W, Nelson PS, Bluemn E, Plymate S, Luo J 2012 Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 72: 3457-3462
37. Simental JA, Sar M, Lane MV, French FS, Wilson EM 1991 Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 266:510-518
38. MacLean HE, Warne GL, Zajac JD 1997 Localization of functional domains in the androgen receptor. J Steroid Biochem Mol Biol 62:233-242
39. Chen Y, Sawyers CL, Scher HI 2008 Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 8:440-448
40. Knudsen KE, Scher HI 2009 Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 15:4792-4798
41. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB 2011 Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17:5913-5925
42. Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, Vakar-Lopez F, Vessella RL, Plymate SR 2011 Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One 6:e27970
43. Chan SC, Li Y, Dehm SM 2012 Androgen receptor splice variants activate AR target genes and support aberrant prostate cancer cell growth independent of the canonical AR nuclear localization signal. J Biol Chem 287:19736-19749
44. Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, Gjyrezi A, Chanel-Vos C, Shen R, Tagawa ST, Bander NH, Nanus DM, Giannakakou P 2011 Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 71:6019-6029
45. Liu JY, Seno H, Miletic AV, Mills JC, Swat W, Stappenbeck TS 2009 Vav proteins are necessary for correct differentiation of mouse cecal and colonic enterocytes. J Cell Sci 122:324-334